David Grossman

Charles Rhyee

Ashok Kumar

Charles Reid

Theodore O'Neill

- DarioHealth Corp. announced a private placement of **2,713,180 shares of common stock** (or common stock equivalents) at **$6.45 per share**, raising approximately **$17.5 million** in gross proceeds.  **[1533998_0001104659-25-093431_tm2526967d1_ex99-1.htm:0]** 
- The offering, which closed on **September 23, 2025**, included **1,154,420 shares of common stock** and **pre-funded warrants to purchase up to 1,558,760 shares of common stock**, with proceeds designated for **general corporate purposes**.  **[1533998_0001104659-25-093431_tm2526967d1_ex99-1.htm:0]** **[1533998_0001104659-25-093431_tm2526967d1_8k.htm:1]** 
- On **September 25, 2025**, the company's Board of Directors initiated a **comprehensive strategic review** to maximize shareholder value, considering options such as a sale, merger, or strategic business combination.  **[1533998_0001104659-25-093431_tm2526967d1_8k.htm:4]**  A special committee and Perella Weinberg Partners have been engaged for this review.  **[1533998_0001104659-25-093431_tm2526967d1_8k.htm:4]**

DarioHealth Announces Private Placement and Initiates Strategic Review

- DarioHealth Corp. filed amended certificates for its Series A-1, Series C, Series C-2, Series D, Series D-1, Series D-2, and Series D-3 Preferred Stock on **September 18, 2025**.  **[1533998_0001104659-25-091718_tm2526500d1_8k.htm:1]** 
- These amendments accelerate the **mandatory conversion period** for Series C and Series D Preferred Stock into common stock or pre-funded warrants, effective **September 18, 2025**.  **[1533998_0001104659-25-091718_tm2526500d1_8k.htm:1]** 
- Holders of preferred stock will receive all accrued and unpaid dividends, including dividend shares or payment-in-kind shares, in addition to the conversion shares.  **[1533998_0001104659-25-091718_tm2526500d1_8k.htm:1]** 
- The Series A-1 Certificate of Designation was amended to provide holders with the option to receive **pre-funded warrants** in lieu of common stock.  **[1533998_0001104659-25-091718_tm2526500d1_8k.htm:1]** 
- No additional securities were issued or sold as a result of these amendments.  **[1533998_0001104659-25-091718_tm2526500d1_8k.htm:1]**

DarioHealth Corp. Amends Preferred Stock Conversion Terms

- DarioHealth Corp. announced a **20-for-1 reverse stock split** of its common stock.  **[1533998_0001104659-25-082513_tm2524185d1_ex3-1.htm:0]** **[1533998_0001104659-25-082513_tm2524185d1_ex99-1.htm:0]** **[1533998_0001104659-25-082513_tm2524185d1_8k.htm:1]** 
- The reverse stock split will become effective at 12:01 a.m. Eastern Time on **August 28, 2025**, with trading on a post-split basis commencing at market open on the same day under the existing symbol "DRIO" and a new CUSIP Number, **23725P 308**.  **[1533998_0001104659-25-082513_tm2524185d1_ex3-1.htm:0]** **[1533998_0001104659-25-082513_tm2524185d1_ex99-1.htm:0]** **[1533998_0001104659-25-082513_tm2524185d1_8k.htm:1]** 
- This action will reduce the outstanding common shares from **47,996,572** to approximately **2,399,829**, with any fractional shares rounded up to the nearest whole share.  **[1533998_0001104659-25-082513_tm2524185d1_ex99-1.htm:0]** **[1533998_0001104659-25-082513_tm2524185d1_8k.htm:1]** 
- The reverse stock split was approved by the Company's board of directors under authority granted by stockholders at the 2025 Annual Meeting held on July 23, 2025.  **[1533998_0001104659-25-082513_tm2524185d1_ex99-1.htm:0]** **[1533998_0001104659-25-082513_tm2524185d1_8k.htm:1]**

DarioHealth (DRIO)